BYOD vs. Provisioned Devices: Why Participant Choice Should Drive Your eCOA Strategy

As smartphones become the default for eCOA, the studies that get it right are the ones that let participants decide what works for them.

Key Takeaways

• BYOD (bring your own device) is a growing default for eCOA data capture, driven by near-universal smartphone ownership, but the strongest device strategy is rarely BYOD-only. It’s BYOD-first, with the choice of a provisioned device available.
• Offering choice protects enrollment, avoids bias, and improves engagement.
• Trust is an important requirement for BYOD success. Clear, specific reassurance on privacy and security, data usage, accessibility, and ongoing support are important elements in building participant trust.

One of the most common questions clinical trial sponsors and contract research organizations (CROs) face as they plan a new study is deceptively simple: should participants use their own smartphone to input data for electronic clinical outcome assessments (eCOAs), or should the trial provide a device instead?

Both approaches have a name in the industry. Bring your own device (BYOD) describes participants using their personal phone, tablet, or computer for study tasks, while a provisioned device is hardware supplied and locked down by the sponsor or eCOA vendor specifically for the trial. The answer to which one to use has changed substantially in the last several years, and increasingly, the best answer isn’t to pick one over the other at all. It’s to offer both, and let the participant decide.

BYOD is No Longer the Exception

The case for BYOD starts with basic math. According to GSMA Intelligence’s The Mobile Economy 2026 report roughly 5.7 billion people—about 70% of the world’s population—now use a smartphone. That level of ubiquity has flipped the old assumption that trials need to supply hardware. Increasingly, participants already own a capable device, and asking them to carry a second one for the study adds friction rather than removing it.

Historically, adoption of BYOD in regulated trials was slowed by two concerns:

• Could data captured across many different device types and screen sizes be considered equivalent?
• Could sponsors manage the practical realities of participants’ own hardware?

Both concerns have been substantially addressed by a decade of usability testing, cognitive debriefing, and quantitative equivalence. For example, work led by eCOA scientists, including uMotif Chief Scientific Officer Florence Mowlem, PhD, has documented how BYOD-collected patient-reported outcome data can meet the bar needed to support regulatory submissions and labeling claims.

This shift is meaningful. For years, Phase 2 and 3 trials defaulted to fully provisioned devices in the name of consistency, and some still do. But with equivalence now demonstrated, and with participants increasingly comfortable—and sometimes reluctant not to—use the device they already carry every day, the industry has moved toward giving people the option rather than assigning them a single path.

Why Device Choice Wins for eCOA Capture

Today, Phase 1b through Phase 3 trials and fully remote, real-world studies like the 100 for Parkinson’s study, where participants report on daily life over an extended period with no clinical site involved, are now often BYOD-first or BYOD-only by design.

Even so, the strongest device strategy isn’t BYOD-only. It’s BYOD by default, with a small pool of provisioned devices available for participants who don’t own a compatible device or would simply prefer not to use their own. This mirrors explicit FDA guidance that participants should never be excluded from a trial, or a study biased, because they lack a suitable personal device. Choice protects enrollment, avoids introducing bias by excluding people without a compatible phone, and respects that comfort with technology varies participant to participant.

Building Participant Trust: What to Communicated about BYOD

Offering a choice only works if participants have the information needed to make a confident decision. A few things deserve clear, plain-language communication as part of informed consent and onboarding, well before someone decides which path to take.

• Privacy and security. This is often participants’ biggest hesitation, and it deserves a direct answer. The study app is built to access only what the trial needs, and it does not see, read, or collect photos, messages, contacts, or anything else on the participant’s phone. Data is encrypted in transit and at rest, regardless of whether the device is BYOD or provisioned.
• Data usage. A common concern is that a study app will eat into a limited cellular data plan. In practice, eCOA solutions transmit small amounts of largely text-based data, and the realistic impact on a typical data plan is minimal.
• Accessibility. Participants with visual, motor, or cognitive limitations should know upfront what accommodations exist, and that those accommodations aren’t contingent on which device option they choose. A well-designed BYOD experience should be just as accessible as a provisioned one.
• Control and support. Participants should understand that choosing BYOD doesn’t mean losing support. They can still turn to the study team if their device changes mid-study, if they run into technical issues, or if they simply change their mind and want to switch to a provisioned device partway through. 

Taken together, these reassurances do more than reduce dropout risk. They also reflect a broader design principle. To capture data well, an eCOA solution has to incorporate a patient-mindset design from the start, one built to remove barriers rather than add them. Offering participants a real, well-explained choice between BYOD and a provisioned device is one of the clearest ways that principle shows up in practice. It goes beyond cost and logistics considerations. It’s a patient-centric consideration that can mean the difference between a participant who stays engaged through the life of a study and one who exits early.

Ready to see how uMotif’s eCOA platform delivers flexibility to support both BYOD and provisioned- device clinical trials and real-world studies? Book a demo with uMotif today.

FAQs

What does “BYOD” mean in an eCOA clinical trial?
BYOD stands for bring your own device. It means participants use their own smartphone, tablet, or computer to complete electronic clinical outcome assessments, rather than using hardware supplied and locked down by the sponsor or eCOA vendor.

Is BYOD-collected eCOA data as reliable as data from a provisioned device?
Yes. A decade of usability testing, cognitive debriefing, and quantitative equivalence research has shown that BYOD-collected patient-reported outcome data can meet requirements for regulatory submissions, even when data is captured across a wide range of device types and screen sizes.

What do participants need to know to make a confident decision about BYOD vs. a provisioned device?
They should receive clear, plain-language information as part of informed consent and onboarding— covering privacy and security (the study app only accesses what the trial needs, and data is encrypted in transit and at rest), data usage (the app transmits small, largely text-based amounts of data, with minimal impact on a cellular plan), accessibility accommodations (available regardless of device choice), and ongoing support (participants can get help or switch device options at any point during the study).